The shares, registered under a Form S-3 filing, are expected to generate approximately $4 million in proceeds. The transaction is set to close on December 3, pending customary conditions.
Roth Capital Partners is serving as the financial advisor for the deal. REVB shares otherwise gained Monday after the company announced FDA acceptance of Gemini IND.
According to data from Benzinga Pro, REVB has a 52-week high of $25.26 and a 52-week low of $0.51.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
Posted In:
